Rybelsus on TikTok: what oral semaglutide actually does

What did @perlaendo actually say?

Honestly, this is a tough one to fact-check. The transcript is largely incoherent, a mix of garbled Spanish and English phrases that appear to be a transcription error or audio processing failure. What we can piece together is that @perlaendo was attempting to explain Rybelsus (oral semaglutide), describing it as a pill taken once daily, taken with a small amount of water, and that users should wait 30 minutes before eating after taking it. The hashtags and caption confirm this was a Rybelsus explainer video from someone identifying as "Dra. Perla Hernández." The phrase that approximates to "una pastilla" (one pill) and references to waiting 30 minutes before eating are the only extractable clinical claims from the transcript.

Does the science back the 30-minute fasting window up?

Yes, and this is actually one of the more important and frequently ignored instructions for oral semaglutide. The 30-minute fasting requirement is real, FDA-mandated label language, and matters more than most patients realize.

Rybelsus contains semaglutide co-formulated with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), an absorption enhancer that temporarily raises local gastric pH to allow semaglutide to cross the stomach lining. Davies et al. (2019, The Lancet) showed that oral semaglutide 14 mg reduced HbA1c by up to 1.4 percentage points in the PIONEER 3 trial. But that efficacy depends entirely on proper dosing conditions. A study by Granhall et al. (2019, Clinical Pharmacokinetics) found that food, even a small meal, reduced semaglutide exposure by approximately 50 to 60 percent. Half the drug. Gone. So the 30-minute window is not a suggestion. It is the mechanism.

What did they get wrong, or right?

The 30-minute pre-meal fasting instruction appears to be correct based on what we can extract. That is worth giving credit for, because it is the single most commonly misunderstood part of Rybelsus adherence in clinical practice.

What is missing, and this is a significant gap for a 277,000-view video, is any mention of who Rybelsus is actually approved for. Rybelsus carries FDA approval for type 2 diabetes management in adults. It is not approved for weight loss. The caption says "descubrir si es para ti" (discover if it's for you), which is a vague invitation that a lay audience might reasonably interpret as an endorsement for off-label weight management use. That framing needs a flag. The PIONEER program trials (Aroda et al., 2019, Diabetes Care) showed weight loss as a secondary outcome, but Rybelsus is not Wegovy. They are not the same product for the same indication, even though both contain semaglutide.

What should you actually know?

If a provider or a TikTok video is suggesting Rybelsus for weight loss, ask direct questions. Rybelsus is semaglutide, the same molecule as Ozempic and Wegovy, but the oral formulation has significantly lower and more variable bioavailability than the injectable forms. Bækdal et al. (2021, Advances in Therapy) confirmed that oral semaglutide achieves roughly 1 percent absolute bioavailability compared to subcutaneous injection, which is why the SNAC absorption enhancer and strict fasting conditions are non-negotiable.

Rybelsus is also not interchangeable with compounded oral semaglutide products. Compounded versions lack the SNAC co-formulation, meaning absorption may differ substantially. Anyone taking Rybelsus should be monitored by a licensed provider, particularly for GI side effects (nausea and vomiting are common, especially during dose escalation) and for interactions with other oral medications taken in that 30-minute window.

• Take Rybelsus with no more than 4 ounces (120 mL) of plain water.
• Wait at least 30 minutes before eating, drinking anything other than water, or taking other oral medications.
• Current approved doses are 3 mg, 7 mg, and 14 mg, titrated over time by your prescriber.
• If you are taking Rybelsus for type 2 diabetes, regular HbA1c monitoring is standard of care.